{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004610684,0.001267118,0.002465228,0.0005863075,0.0002453,0.000966606,0.0006505223,0.001035594,0.003281882],"category_scores_gemma":[0.004557875,0.0004718846,0.003599701,0.0005857389,0.0008437314,0.001303961,0.0004604259,0.002068508,0.0004045939],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001062009,"about_ca_system_score_gemma":0.0005846418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005156995,"about_ca_topic_score_gemma":0.00171987,"domain_scores_codex":[0.9977018,0.001572963,0.0001561477,0.0002551998,0.0001181151,0.0001957784],"domain_scores_gemma":[0.9970365,0.001680623,0.000721331,0.0001954867,0.0000796403,0.0002864994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9762517,0.001541024,0.002200026,0.0004498552,0.003045188,0.00003522774,0.00006083401,0.0005912848,0.001098493,0.00005551014,0.000293942,0.01437683],"study_design_scores_gemma":[0.8068581,0.1589113,0.02463636,0.0001409268,0.005647557,0.0001451757,0.00009211671,0.001322762,0.0007014854,0.0003490678,0.001142163,0.00005291372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990703,0.006063764,0.0003509795,0.0002435071,0.0001497291,0.0007176925,0.0007722963,0.00003117355,0.0009678557],"genre_scores_gemma":[0.9945132,0.0017416,0.0005507201,0.0004577847,0.00017701,0.0005268799,0.001131916,0.00001347419,0.0008875315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004610684,"threshold_uncertainty_score":0.02438396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1471450445887598,"score_gpt":0.4395473762209945,"score_spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}